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ABSTRACT Immunocytochemical, biochemical, and molecular genetic studies indicate that apolipoprotein E (apoE) plays
an important role in the process of amyloidogenesis-. However, there is still no clear translation of these data into the
pathogenesis of amyloidosis-. Previous studies demonstrated sodium dodecyl sulfate (SDS)-resistant binding of apoE to the
main component of Alzheimer’s amyloid-A and modulation of A aggregation by apoE in vitro. To more closely characterize
apoE-A interactions, we have studied the binding of thrombolytic fragments of apoE3 to A in vitro by using SDS-
polyacrylamide gel electrophoresis and intrinsic fluorescence quenching. Here we demonstrate that SDS-resistant binding of
A is mediated by the receptor-binding, N-terminal domain of apoE3. Under native conditions, both the N- and C-terminal
domains of apoE3 bind A; however, the former does so with higher affinity. We propose that the modulation of A binding
to the N-terminal domain of apoE is a potential therapeutic target for the treatment of amyloidosis-.
INTRODUCTION
The pathology of Alzheimer’s disease (AD) brain involves
synaptic alterations, neuronal loss, gliosis, and formation of
two types of structures: neurofibrillary tangles (NFTs) and
amyloid-. Amyloid deposition is an invariant feature of
AD, commonly believed to be responsible for a cascade of
events leading to dementia, and finally death of AD patients
(Selkoe, 1994). The major component of the amyloid accu-
mulated in the leptomeningeal and cerebral vessels as amy-
loid angiopathy and in the neuropil as senile plaques (SPs)
is a 39–43 amino acid hydrophobic peptide referred to as
amyloid -peptide (A) (Glenner and Wong, 1984; Masters
et al., 1985). A is a proteolytic fragment of the larger
transmembrane glycoprotein termed amyloid- precursor
protein (APP) (Goldgaber et al., 1987; Robakis et al., 1987;
Tanzi et al., 1988). Proteolysis of APP by so-called - and
-seretases leads to the secretion of A into the extracellu-
lar space by virtually all types of cells examined so far. This
soluble form of A (sA) is present in low nanomolar range
in both plasma and cerebrospinal fluid (CSF) (Seubert et al.,
1992; Shoji et al., 1992; Vigo-Pelfrey et al., 1993). Factors
responsible for the exclusive deposition of A only within
the brain tissue remain elusive.
Recent studies suggest that the so-called amyloid-associ-
ated proteins such as apolipoproteins, serum amyloid P
component, 1-antichymotrypsin, or proteoglycans may
contribute significantly to the progression of amyloidogen-
esis- and A toxicity (recent review: Wisniewski et al.,
1997). One of these proteins, apolipoprotein E (apoE), has
received special attention after discovery of the genetic
association of apoE polymorphism with late-onset AD
(Strittmatter et al., 1993a). ApoE is a 34-kDa glycoprotein
whose primary role involves lipid transport and redistribu-
tion among different tissues (Mahley, 1988). ApoE is a
major apolipoprotein in the brain and in CSF, and its ex-
pression is increased significantly after central and periph-
eral nerve injuries (Ignatius et al., 1986; Kida et al., 1995b).
Studies in cell culture and in knockout mice indicate that
apoE participates, in an isoform-specific manner, in tissue
regeneration and remodeling (Nathan et al., 1994; Masliah
et al., 1995).
The three major apoE isoforms in humans, apoE2, apoE3,
and apoE4, are products of three alleles, 2, 3, and 4, of
a single apoE locus on chromosome 19 (Utermann et al.,
1979). In the general population, the 3 allele is the most
common, accounting for78% of all apoE alleles (Hallman
et al., 1991). The frequency of the 4 allele is increased
significantly in the population of late-onset sporadic and
familial AD patients (Corder et al., 1993; Saunders et al.,
1993). However, in Down’s syndrome and AD associated
with presenilin mutations, which typically develop early,
and severe amyloidosis-, apoE 4 is not increased in
comparison to the general population, although apoE dep-
osition in amyloid- is similar to that in sporadic AD (Van
Gool et al., 1995; Levy-Lahad et al., 1995; Kida et al.,
1995a; Gearing et al., 1995; Houlden et al., 1998). Despite
intensive study, there is still no clear translation of genetic
data into the pathogenesis of amyloidogenesis-. Further-
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more, the precise role of apoE in normal brain functioning
and the molecular mechanisms underlying the physiological
functions of apoE are also still poorly understood.
We and others have shown direct interactions between
apoE and A by demonstrating in vitro binding of A to
apoE (Wisniewski et al., 1993; Strittmatter et al., 1993a,b;
LaDu et al., 1994), revealing the conformation-dependent
manner of A-apoE interactions (Golabek et al., 1996) and
showing that apoE is capable of modulating the conforma-
tional and fibrillogenic properties of A acting as a patho-
logical chaperone (Wisniewski et al., 1994; Soto et al.,
1996). The idea that apoE may be involved directly in A
fibrillogenesis was strengthened recently by data showing
that platelet-derived growth factor-APP transgenic mice
with apoE knockout show a prominent reduction of amy-
loid- deposits, and especially of thioflavin-S-positive
plaques, which are highly fibrillized (Bales et al., 1997).
ApoE contains two functionally different domains: the N-
terminal domain, which encompasses a receptor binding
region, and the C-terminal domain, which is responsible for
lipid binding (Mahley, 1988). Thus, to more closely char-
acterize apoE-A interactions, we have studied at present
the binding of A to both the N- and C-terminal fragments
of apoE. Here we report that the strong, sodium dodecyl
sulfate (SDS)-resistant A binding to apoE3 is mediated
by the N-terminal, receptor-binding domain of the apoE
molecule.
MATERIALS AND METHODS
Synthetic peptide and proteins
A 1–40 was custom synthesized by the W. M. Keck Foundation (New
Haven, CT). Purity of the peptide was verified by analytical reversed-
phase-high-performance liquid chromatography and mass spectrometry. A
stock solution of A was made at 2 mg/ml in 50% acetonitrile, 0.1%
trifluoroacetic acid, quantitated by amino acid analysis on the Waters
AccQ-Tag System (Millipore Corp., Milford, MA), and stored lyophilized
in aliquots. Recombinant ApoE3 was obtained from BioTechnology Gen-
eral (Israel, lot 738-1) (Vogel et al., 1985).
ApoE cleavage by thrombin
To 10 mg of human recombinant apoE3 dissolved in 5 ml of 100 mM
NH4HCO3, pH 8.5, thrombin was added at a weight ratio of 1:100 (throm-
bin:apoE) and incubated at room temperature for 2 h. After that, an
additional portion of thrombin was added to a final concentration of 1:50,
and the cleavage was continued for two more hours. After cleavage, the
sample was lyophilized; dissolved in 2 ml of 6 M GuHCl, 100 mM Tris
(pH 7.4), 2 mM EDTA, and 1% -mercaptoethanol (buffer A) and incu-
bated at room temperature for 10 min. ApoE fragments were isolated after
gel exclusion chromatography on a Sephadex G-100 column (2 180 cm),
equilibrated, and developed with buffer A. The flow rate was 6 ml/h, and
absorbance was monitored at 280 nm. Absorbance peaks corresponding to
10 and 22 kDa, respectively, were pooled, dialyzed against 50 mM
NH4HCO3 (pH 8.5), lyophilized, dissolved in ddH2O, and analyzed by
SDS-polyacrylamide gel electrophoresis and N-terminal sequencing.
SDS-resistant binding analysis
Two micrograms of A was mixed with 2 g of human recombinant
apoE3, 10 g of human plasma very-low density lipoproteins (VLDL), or
2 g of the N-terminal (N-apoE) or the C-terminal (C-apoE) fragments of
apoE and incubated in 20 l of 0.1 M Tris (pH 7.4) overnight at 37°C. Five
microliters of 5 Laemmli sample buffer without reducing agent was then
added; samples were incubated for 10 min at 37°C, loaded onto 15%
SDS-polyacrylamide gel (Scha¨gger and von Jagow, 1987), and electropho-
resed at a constant current of 20 mA. After electrophoresis, gel was either
stained with Coomassie blue or electrotransferred onto nitrocellulose mem-
brane by the method of Towbin et al. (1979). After transfer, membrane was
saturated with 5% nonfat dry milk (NDM) in phosphate-buffered saline
(150 mM NaCl, 20 mM sodium phosphate, pH 7.4) and incubated with
primary monoclonal antibody (mAb) 6E10, raised against amino acids (aa)
1–16 of A (Kim et al., 1988), at 1:1000; mAb 3D12 (Biodesign, Ken-
nebunk, ME), recognizing an epitope in the C-terminal domain of apoE, at
1:1000; or mAb 9H8 (Biodesign), recognizing an epitope in the N-terminal
domain of apoE, at 1:500, in 0.5% NDM/0.5% Tween 20/phosphate-
buffered saline. Then blots were washed, incubated with secondary anti-
body conjugated to horseradish peroxidase, and developed with an en-
hanced chemiluminescence (ECL) kit from Amersham Pharmacia
(Piscataway, NJ). For amino acid sequencing, gels were transferred onto
polyvinyl pyrrolidine fluoride membrane and stained with Coomassie blue,
and the adequate bands were excised and sequenced.
Fluorescence quenching
To measure the affinity of A for N-apoE and C-apoE, we have used a
fluorescence quenching spectroscopy, taking advantage of the fact that A
does not contain any tryptophan residue, whereas apoE has six of them.
ApoE3, N-apoE, and C-apoE were dissolved at 2, 10, and 4.5 M,
respectively, in 0.1 M Tris (pH 7.4), and their fluorescence spectra were
recorded at 290–415 nm with an excitation wavelength of 285 nm on a
Perkin-Elmer LS50B spectrofluorimeter (Perkin-Elmer, Norwalk, CT),
with the slits set at 2.5 nm. Similarly, fluorescence spectra of apoE3,
N-apoE, and C-apoE were recorded in the presence of increasing concen-
trations of A (2–500 nM) after 20 min of equilibration and were corrected
for residual fluorescence of the peptide itself. The fluorescence change at
340 nm was plotted versus A concentration, and the resulting curves were
analyzed by nonlinear regression fit with GraphPad Prism software.
Other methods
VLDLs from the fresh frozen human plasma were isolated by ultracentrif-
ugation as described previously (Koudinov et al., 1994). Protein concen-
tration was quantitated by the method of Bradford with bovine serum
albumin (Pierce) as a standard. Amino-terminal sequencing was performed
on a 477A protein sequencer, and the resulting phenylthiohydantoin de-
rivatives were identified with the use of an on-line phenylthiohydantoin-
derivative analyzer (Applied Biosystems, Foster City, CA).
RESULTS
SDS-resistant binding
First we analyzed the SDS-resistant properties of A bind-
ing to the thrombolytic fragments of apoE3. Thrombin
cleaves apoE at positions 196 and 215, giving rise to two
fragments: the N-terminal fragment, with a molecular mass
of 22 kDa, and the C-terminal fragment, with a molecular
mass of 10 kDa (Fig. 1). Incubation of A with N-apoE
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and C-apoE led to the formation of SDS-resistant com-
plexes with the N-terminal fragment but not the C-terminal
fragment (Fig. 1). This complex was readily visualized by
Coomassie staining of the gel and by Western blotting,
using monoclonal antibodies directed against A (6E10)
and apoE (9H8) (not shown). N-terminal sequencing of this
N-apoE/A26-kDa complex revealed the equimolar pres-
ence of apoE and A, suggesting a 1:1 molar ratio in the
complex. The sequences obtained were the following:
D A E F R A
and
K V E Q A apoE.
In vivo, most of the apoE is associated with lipid particles
(lipoproteins) (Mahley, 1988). The binding of the protein to
lipids is mediated by the C-terminal domain. Thus, in the
lipoprotein environment, this apoE domain most likely will
not be available for interaction with A. To analyze whether
the lipidated protein is able to bind A, we performed
SDS-resistant binding studies with the native apoE from
human plasma in the form of purified VLDL particles.
Incubation of the VLDL with A, by a method similar to
that used for purified apoE3, led to the formation of a
38-kDa complex, readily detected with both anti-A and
anti-apoE antibodies (Fig. 2). These data indicate that SDS-
resistant binding of A to apoE is not inhibited by the
association of apoE with lipids and therefore is not likely to
be mediated by the C-terminal domain of apoE.
Monitoring apoE-A interaction in solution by
fluorescence spectroscopy
To estimate the parameters of A binding to apoE3 and its
fragments in solution, we used a method based on monitor-
ing changes in the protein intrinsic fluorescence upon its
binding to A. Full-length apoE3 incubated alone when
excited at 285 nm shows a fluorescence emission spectrum
with a maximum at 345 nm (Fig. 3 A), which is typical of
tryptophan residues in a protein environment. Incubation of
apoE with increasing concentrations of A caused a decline
in its intrinsic fluorescence. When the changes in apoE
fluorescence were plotted against A concentration, we
obtained a hyperbolic curve with a maximum at 200 nM
A (Fig. 3 B). Nonlinear regression analysis of the data
revealed an apparent dissociation constant for apoE3/A
complex of KD  11.65 nM, which is considered a high-
affinity interaction and is very close to the value reported
previously for a solid-phase binding assay (Golabek et al.,
1996). Scatchard transformation of the fluorescence
changes according to the Stern-Volmer equation (F/F0/
[A]  KFmax  K(F/F0) resulted in a good fit to the
two-binding-site populations model, with dissociation con-
stants KD1 	 2 nM and KD2 	 31 nM (Fig. 3 C).
FIGURE 1 SDS-resistant binding of apoE fragments to A. Incubation
of A with N-terminal and C- terminal domains of apoE3 led to formation
of SDS-resistant complexes with the N-terminal fragment (lane 5, arrow-
head) but not with the C-terminal fragment (lane 3). Lane 1: Molecular
mass markers; lane 2: A alone; lane 4: C-terminal fragment of apoE
alone; lane 6: N-terminal fragment of apoE alone. Coomassie blue-stained
gel.
FIGURE 2 ApoE binding to A is not inhibited by association of apoE
with lipids. Incubation of the human plasma VLDL with A led to the
formation of an38-kDa complex, readily detected with anti-A antibody
(lane 3), similar to the complex of A and purified apoE3 (lane 2).
Because of the lower amount of apoE in VLDL and lower affinity of
anti-apoE antibody than anti-A antibody, the apoE/A complex in lane 7
was detected only after prolonged exposure (not shown). Lane 1: A alone;
lanes 2 and 5: A 
 apoE; lanes 3 and 7: A 
 VLDL; lanes 4 and 8:
VLDL alone; lane 6: apoE alone. Lanes 1–4: mAb 6E10, anti-A; lanes
5–8: mAb 3D12, anti-apoE. ApoE/A complexes are indicated by an
arrow.
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To determine where the two binding sites in the apoE
molecule are located, binding of A to the isolated domains
was studied by fluorescence assay. The fluorescence spectra
of N-apoE and C-apoE in the absence of A were shifted
slightly to the red (maxima at 347 and 350 nm, respec-
tively), suggesting that the tryptophan residues were more
exposed to the solvent than in the intact protein (Fig. 4, A
and B). The presence of A led to moderate changes in
C-apoE fluorescence, whereas the changes in N-apoE fluo-
rescence in the presence of increasing A concentration
were much higher and similar to the changes produced in
the full-length apoE3 spectrum. Changes in fluorescence of
apoE fragments were plotted against A concentration, and
apparent dissociation constants for binding of apoE frag-
ments to A were calculated with the help of curve-fitting
software. The calculated KD for the N-apoE/A complex
was 11 nM, whereas the KD for C-apoE/A was 66 nM
(Fig. 4 C). Scatchard transformation of fluorescence data
with the Stern-Volmer equation showed a simple population
of binding sites for each apoE domain with dissociation
constants of 10 nM and  45 nM for the N-apoE and
C-apoE, respectively (Fig. 4, D and E).
DISCUSSION
Several lines of evidence suggest that apoE plays an impor-
tant role in modulating amyloidosis-. The aim of this study
was to characterize apoE-A interaction in terms of the
protein regions implicated in the binding to the peptide. Our
data show that delipidated apoE3 interacts with A through
two different binding sites, located in the N- and C-terminal
functional domains of apoE. N-apoE binds A with 4–10
times higher affinity than C-apoE. We have shown previ-
ously by using a solid-phase assay that the whole apoE3
molecule binds A with a KD of 20 nM (Golabek et al.,
1996), and in the present study we obtained a KD of 11
nM by using a fluorescence binding assay in solution. A
similar KD value (10 nM) for apoE/A heterodimer was
obtained by others using surface plasmon resonance (Shu-
vaev and Siest, 1996). At present, we demonstrate that the
SDS-resistant binding of A to apoE can be attributed to the
N-terminal domain of apoE and that the KD of the complex
formed by the N-terminal domain of apoE with A 1–40 is
similar to the dissociation constant of the complex formed
by the whole apoE molecule with A 1–40. Thus it is
predominantly the N-terminal domain of apoE that is re-
sponsible for the stability of apoE/A complexes.
These results differ from those published in the past by
Strittmatter and colleagues (1993b) and Pillot et al. (1999),
who found that residues 244–272 of apoE are critical for
A binding. The different results might be partially attrib-
uted to the distinct methodologies used. In addition, our
earlier data indicate that these discrepancies might be
caused by different A peptides used for the experiments
(Golabek et al., 1996). Strittmatter and colleagues per-
FIGURE 3 ApoE binding to A under native conditions measured by
using fluorescence quenching. (A) Decline of apoE3 intrinsic fluorescence
(ƒ) after incubation with increasing concentrations of A: ‚, 5 nM; ‚, 20
nM; E, 50 nM; , 200 nM. (B) Nonlinear regression analysis of apoE
fluorescence changes revealed a saturable binding with Bmax  197 nM
and a dissociation constant for the complex KD 11.65 nM. (C) Scatchard
transformation of the fluorescence changes according to the equation
F/F0/[A]  KFmax  K(F/F0 resulted in a good fit to the two-
binding-site model of interaction for the apoE/A complex, with dissoci-
ation constants KD1 	 2 nM (– – –) and KD2 	 31 nM (——).
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formed their experiments by using a shorter A peptide, A
1–28, of unknown conformation. Usually, this particular A
peptide shows an unordered structure at physiological pH
(Barrow and Zagorski, 1991). On the other hand, studies of
Pillot et al. (1999) utilized various fragments of A pep-
tides, excluding the most physiologically relevant full-
length A peptide (1–40 or 1–42). In contrast, we have
chosen for our studies A 1–40, a synthetic peptide with an
FIGURE 4 Native binding of apoE domains to A. (A and B) N-terminal (A) and C-terminal (B) fragments of apoE3 were incubated with increasing
concentrations of A, and their fluorescence spectra were recorded: ƒ, 0 nM of A; ‚, 5 nM; , 20 nM; E, 50 nM; , 200 nM. (C) Both N-terminal
(– – –) and C-terminal (——) domains of apoE3 saturably bound A, resulting in dissociation constants KD equal to 11 nM and 66 nM, respectively.
(D and E) Scatchard transformation of the fluorescence changes induced by the interaction of A with N-apoE (D) and C-apoE (E), fit with a single binding
site population with KD 	 11 nM and 46 nM, respectively.
1012 Golabek et al.
Biophysical Journal 79(2) 1008–1015
intact C terminus, the length of which corresponds to the
main soluble A species released by cells into physiological
fluids. The A1–40 selected for our experiments had a
-sheet content of 15–20%. According to our previous
studies, the secondary structure of A peptides is an impor-
tant factor determining their ability to form complexes with
apoE; peptides with high -sheet content show higher af-
finity for apoE than A peptides with low -sheet content
(Golabek et al., 1996). The binding of the N-terminal do-
main of apoE to A also was observed by others; however,
it appeared to be weaker than complexes formed by A with
full-length apoE (Chan et al., 1996).
The biological consequences of apoE/A interactions are
far from being elucidated. The N- and C-terminal domains
of apoE molecule represent two independently folded struc-
tures connected by a hinge region (Aggerbeck et al., 1988;
Wetterau et al., 1988; recent review: Weisgraber, 1994).
The N-terminal domain of apoE has a stable globular struc-
ture, whereas the C-terminal domain is unstable in aqueous
solvents and forms tetramers similar to the full-length, pu-
rified apoE. When each fragment is denatured with guani-
dine, its unfolding closely resembles the two transitions
pattern characteristic of a full-length apoE molecule (Wet-
terau et al., 1988). On the basis of the observation that the
thrombin-cleaved C-terminal fragment of apoE showed fi-
brillogenic properties in vitro, it was proposed that this
fragment of apoE might constitute a fibrillar component of
-amyloid deposits in vivo (Wisniewski et al., 1995). Full-
length apoE as well as both the N- and C-terminal fragments
have indeed been isolated from amyloid deposits in AD
brain (Wisniewski et al., 1995; Naslund et al., 1995). These
results have also been confirmed by immunohistochemistry
with the use of several antibodies directed to different
regions of apoE (Namba et al., 1991; Wisniewski and Fran-
gione, 1992; Aizawa et al., 1997).
Controversial studies have been published on the effect of
apoE on A fibrillogenesis. Several reports suggested that
apoE might act as an inhibitor (Evans et al., 1995; Wood et
al., 1996; Naiki et al., 1997) or as a promoter (Wisniewski
et al., 1994; Ma et al., 1994; Castan˜o et al., 1995) of A
fibrillogenesis. Recent studies in apoE knockout mice with
experimentally induced AA amyloidosis or A amyloidosis
strongly support the notion that apoE promotes, not inhibits,
the process of amyloidogenesis. Amyloid-A deposition was
clearly reduced in apoE knockout mice (Hoshii et al., 1997;
Kindy and Rader, 1998). Of special importance is the ob-
servation that amyloid load can be restored in these animals
after the expression of human apoE3 gene (Kindy and
Rader, 1998). Similarly, APP transgenic/apoE knockout
mice demonstrate a dramatic decrease in amyloid load and
lack of thioflavin-S-positive plaques in comparison with
transgenes with a functional apoE gene (Bales et al., 1997,
1999). Seemingly opposite results were obtained recently
by Holzman et al. (1999), who demonstrated the suppres-
sion of early amyloid deposition in human apoE3 and
apoE4/APP transgenic mice on a mouse apoE null back-
ground. However, these authors used astrocyte-specific glial
fibrillary acid protein promoter to drive the expression of
human apoE in these animals. Unlike those of mice, human
brain neuronal cells stain strongly for apoE (Han et al.,
1994). Therefore, it is conceivable that the enhancement of
amyloid deposition by apoE results from the specific inter-
action of neuronal apoE/neuronal A, either within cells or
upon their secretion, whereas apoE secreted by glial cells
could participate in A clearance, as suggested by Rebeck
et al. (1993).
Considering that apoE genotype along with aging is a
major risk factor for AD, the precise characterization of
apoE/A interaction may reveal novel therapeutic targets
for the treatment of amyloidoses-.
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